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The Faculty of Public 
Health is pleased to be 
part of this report. We 
need a new, people-
centred approach to drug 
policy, rooted in public 
health and the best 
available evidence. This 
report is an important part 
of a growing, powerful 
evidence base that sets 
out what that approach 
should look like. The time 
for reframing the
global approach to illicit drugs is long overdue. 
The imbalance between criminal justice and health 
approaches to illicit drugs is counterproductive. 
Criminalisation and incarceration for minor, non-violent 
offences worsen problems linked to illicit drug use, such 
as social inequality, violence and infection. Possession 
and use should be decriminalised and health 
approaches prioritised.
Drug harm operates across a socio-economic and 
ethnic gradient. Illicit drug use worsens health 
inequalities and health-related harms, including the 
stigma of a criminal record, violence, debt, social 
breakdown and infection risk. Addressing economic and 
social disadvantage is essential to addressing the root 
causes of addiction and addictive behaviours.
A harm-reduction approach is fundamental to tackling 
these problems. Recovery – reducing chaotic lifestyles 
and enabling educational, employment and housing 
opportunities – is also important. However, the 
dominant concept of recovery as equating to abstinence 
is limiting.
Drug education in schools – provided through the 
medium of high quality Personal, Social, Health and 
Economic (PSHE) education – should be a key part 
of the curriculum, and taught from an early age. 
Educational approaches for young people must be 
evidence-based, interactive and peer-led – ‘just say no’ 
just won’t cut it.
1 Foreword
Drugs policy discourse 
throughout the 20th century 
was dominated by the 
mantra that drug use is a 
criminal activity, rather than 
a health issue. However, 
despite an approach centred 
around prohibition and law 
enforcement, this policy has 
failed to curtail demand or 
supply, or reduce the harm 
that drugs cause. We have also 
tended to view legal and illegal 
drugs differently, when the
evidence suggests that there is similarity in the harm they 
cause to health and wellbeing, and that in some cases certain 
illegal drugs may cause lower levels of harm than some  
legal substances.
It would therefore be fair to say this approach has failed on 
many levels. It has criminalised and stigmatised a significant 
proportion of the population, many of whom are the most 
vulnerable people in society. It has rendered illegal drugs 
very much more dangerous than they might be in a regulated 
market. It has unhelpfully skewed precious law enforcement 
resources – dictated by the legal status and classification of 
the drug rather than the harm they may cause. And it has left 
the public confused about drug harm, which could undermine 
efforts to encourage individuals to reduce the risks to their 
health and wellbeing.
This report seeks to explore a different approach to drug policy 
by setting out how we can move away from viewing drug use  
through an ideological lens and instead take an evidence-based 
approach aimed at improving and protecting the public’s 
health and wellbeing. The objective would be to reduce drug-
related harm – this would include minimising substance 
abuse, but this would not be the end in and of itself.
Our approach seeks to focus development of drugs policy 
on minimising the specific harms drugs can cause to people 
and society. This would necessarily involve rebalancing our 
approach to legal and illegal drugs, doing our utmost to 
prevent drug abuse in the first place, but also ensuring that 
harm is minimised for those who do use substances, whilst 
ensuring that those responsible for the harm are brought to 
account. It is time we considered taking a new line on drugs.
Dr Fiona Sim OBE
Chair  
Royal Society for Public Health
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2  Executive Summary
1. ‘Drugs’ are not just those substances that are currently illegal. They also include 
 socially-embedded legal substances, such as alcohol and tobacco, used by the   
 majority of people in the UK. Drugs strategy must reflect this reality, and not create  
 artificial and unhelpful divisions.
2. All drug use increases the risk of some form of related harm, be it to the    
 individual, those around them, wider society, or all three. However, drug harm   
 cannot be objectively measured on a single scale – it is multi-faceted, including   
 physical, psychological and social harm, both to the user and to others. Every drug 
 has a different harm profile across these categories, and so it is too simplistic to   
 only say ‘drug A is more harmful than drug B’.
3. Illegal drug use in the UK rose through the 1960s to 1990s, but has fallen over the   
 course of the past decade. However, this overall fall hides the increase in the use of 
 Class A drugs – those deemed most harmful under the existing classification 
 system – and the take up of new psychoactive substances, the rate of which   
 remains uncertain. More importantly, drug harm is not declining in line with the fall 
 in use, and there have been increases in many types of harm including the number  
 of deaths. Levels of drug harm, not simply levels of drug use, should be taken into   
 account when considering the success of drugs policy.
4. At both individual and population level, alcohol and tobacco cause far greater harm 
 to health and wellbeing than many of their illegal counterparts. Tobacco kills the   
 most people and alcohol is not far behind, with death rates from alcohol misuse   
 on the rise. Alcohol and tobacco use alone costs society more than all Class A drugs  
 combined, and our policy priorities should reflect this.
5. Only a quarter of the public believe the current UK drugs strategy is effective in   
 protecting their health and wellbeing.
6. The current legal framework is confusing for the public, and does not correlate with  
 evidence-based assessment of relative drug harm. This situation is likely to get   
 worse with the recent introduction of the Psychoactive Substances Act.
This report, ‘Taking a New Line on Drugs’, comes at a timely moment for drugs strategy both in the UK 
and across the world. The special session of the United Nations General Assembly on the world drug 
problem, which took place in New York in April 2016, represented a missed opportunity to move on from 
the ‘war on drugs’ and take a new approach, despite the pioneering policies focused on public health 
and harm reduction being pursued by a number of nations. In the UK, the Psychoactive Substances Act 
came into effect in May 2016, and we await a refreshed Government drugs strategy later in the year.
‘Taking a New Line on Drugs’ assesses the situation in the UK as regards rising health harm from 
illegal drugs, with reference to their context within the wider ‘drugscape’ of legal drugs such as alcohol 
and tobacco, and sets out a new vision for a holistic public health-led approach to drugs policy at 
a UK-wide level.
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7. Internationally, increasing numbers of countries, alongside the World Health 
 Organisation, are recognising the failures of prohibition-centric drugs policies.   
 Instead, they are moving towards a public health approach which focuses primarily  
 on reducing the overall level of harm associated with drug use, rather than the level  
 of drug use itself, accepting that a certain level of use will always remain inevitable  
 among those who are unable or unwilling to stop. International pioneers such as 
 the Netherlands, Canada and Portugal have seen encouraging results, with reduced  
 levels of drug harm and without the increases in use feared from decriminalisation.
8. From a public health perspective, the purpose of a good drugs strategy should be to  
 improve and protect the public’s health and wellbeing by preventing and reducing the 
 harm linked to substance use, whilst also balancing any potential medicinal benefits. 
 RSPH is calling for the UK to consider exploring, trialling and testing such an   
 approach, rather than one reliant on the criminal justice system. This could include:
 a. Transferring lead responsibility for UK illegal drugs strategy to the Department   
  of Health, and more closely aligning this with alcohol and tobacco strategies.
 b. Preventing drug harm through universal Personal, Social, Health and Economic   
  (PSHE) education in UK schools, with evidence-based drugs education as a   
  mandatory, key component.
 c. Creating evidence-based drug harm profiles to supplant the existing 
  classification system in informing drug strategy, enforcement priorities, and   
  public health messaging.
 d. Decriminalising personal use and possession of all illegal drugs, and diverting 
  those whose use is problematic into appropriate support and treatment   
  services instead, recognising that criminalising users most often only opens   
  up the risk of further harm to health and wellbeing. Dealers, suppliers and   
  importers of illegal substances would still be actively pursued and prosecuted,   
  while evidence relating to any potential benefits or harm from legal, regulated   
  supply should be kept under review.
 e. Tapping into the potential of the wider public health workforce to support   
  individuals to reduce and recover from drug harm.
From a public health 
perspective, the purpose 
of a good drugs strategy 
should be to improve 
and protect the public’s 
health and wellbeing 
by preventing and 
reducing the harm 
linked to substance use, 
whilst also balancing 
any potential medicinal 
benefits.
3  Background
This section sets out what we mean when we talk about ‘drugs’, the harm these 
drugs can do, and how that harm has been developing over time. 
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3.1 What are drugs and why do we use them?
When many people think of ‘drugs’, they tend to think of those substances the use and 
supply of which is prohibited by the state. The use of alcohol and tobacco has become 
so socially embedded that we no longer tend to think of them as drugs at all – yet this, 
in reality, is what they are. A dictionary definition of a drug is as ‘a medicine or other 
substance which has a physiological effect when ingested or otherwise introduced into 
the body’1. Alcohol and tobacco (more specifically, the nicotine it contains) are among 
those drugs classed as psychoactive, in that they affect the mental processes of the 
user2. It is these psychoactive drugs, as a whole, that form the subject of this report.
In recognition of this we should recalibrate our understanding to acknowledge that 
most UK adults use psychoactive drugs. Of those that are legally available, eight in 
10 drink alcohol3, and around one in five smoke tobacco4. There are also significant 
numbers who take prescribed psychoactive drugs, with one in 11 having used 
prescribed antidepressants in the past year5 and one in 10 regularly taking  
sleeping pills6.
A smaller but significant number use illegal drugs (based on self-report past year use): 
most common is cannabis (around one in 15), followed by cocaine (almost one in 45) 
and ecstasy (around one in 60). A much smaller number (one in 1,000) use opiates, 
including heroin and methadone7. Illegal drug use is higher among young people, with 
one in 10 11-15 years olds reporting having taken an illegal drug in the past year8. 
The prevalence of use of new psychoactive substances (NPS) – substances that 
mimic the effects of a number of illegal drugs, but with a different molecular 
structure – remains a relatively unknown quantity, although it is thought to be 
largely confined to those who also use traditional illegal drugs9.
Based on their effects and mode of action in the body, psychoactive 
drugs can be roughly divided into three classes (although it should be 
noted that some drugs, such as cannabis, straddle more than one of 
these categories)10:
•	 depressants, including alcohol and heroin, which slow normal  
 brain function, provide pain relief and euphoria;
•	 stimulants, including cocaine and nicotine, which elevate mood  
 and alertness;
•	 psychedelics/hallucinogens, including LSD and  
 magic mushrooms, which alter perception of reality.
We should recalibrate 
out understanding 
to acknowledge that 
most UK adults use 
psychoactive drugs.
TAKING A NEW LINE ON DRUGS: 3 BACKGROUND  RSPH 2016
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ALCOHOL 38,849,040
TOBACCO 9,344,200
POWDER COCAINE 743,000
ECSTASY 500,000
MEPHADRONE 205,000
LEGAL
CRACK COCAINE 47,000
KETAMINE 189,000
CANNABIS 2,067,000 
MAGIC MUSHROOMS 115,000
LSD 99,000 HEROIN 33,000
ILLEGAL
METHADONE 
49,000
UK drug users by category and legal status
•=Depressants   •=Stimulants   •=Psychedelics/hallucinogens
Source: Home Office11
PRESCRIPTION
3  Background
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People initially experiment with drugs for a variety of reasons: out 
of curiosity, because of peer pressures or rebelliousness. This initial 
experimentation typically occurs at a young age – up to half of 
young people may have experimented with illegal drugs or solvents 
by the time they are 1612. They continue to use them, among other 
reasons, to relax, to become intoxicated, for pleasure, for escapism, 
to lose inhibitions, to enhance socialising and other activities, to self-
medicate and relieve pain, to improve mood or, in some cases, to 
relieve cravings linked to dependence13. This dependence can also 
result from prolonged use of prescribed medication, such as opiate-
based painkillers.
Law enforcement and historical, social and economic forces all help 
determine who is exposed to which drugs. Poverty, unemployment 
and social deprivation are particularly significant factors that 
contribute to more risky patterns of substance use15.
Why people use drugs 
2 IN 5  
TO RELIEVE 
PAIN
ALMOST  
1 IN 5  
TO RELIEVE 
DEPRESSION 
AND/OR 
ANXIETY
1 IN 3  
TO FEEL 
MORE 
RELAXED
And why they don’t 
1 IN 4  
SAY IT’S TOO 
RISKY OR 
HARMFUL
1 IN 6  
DON’T LIKE 
OR DESIRE 
THE EFFECTS
1 IN 10  
DON’T WANT  
TO RISK 
ADDICTION
1 IN 10  
DON’T 
LIKE OR 
DESIRE THE 
EFFECTS
1 IN 4  
SAY IT’S TOO 
RISKY OR 
HARMFUL
1 IN 10 
DON’T WANT 
TO RISK 
ADDICTION
ALCOHOL OR TOBACCO
ILLEGAL DRUGS
2 IN 5  
TO BE 
SOCIABLE
Source: RSPH public opinion survey14.
However, some individuals are more likely to engage in riskier 
substance use than others16. Those with pre-existing mental health 
conditions, including anxiety and depression, are particularly at 
risk17. It is estimated that up to half of people with mental health 
problems also have current alcohol or other drug issues18.
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3.2 Drug-related harm
The majority of people who use drugs (broadly defined) do so without experiencing significant health, financial or other harm. 
However, all drug use increases the risk of some form of related harm, be it to the individual, those around them, wider society, 
or all three. 
The 16 harm criteria agreed on by the Advisory Council on the Misuse of Drugs (ACMD), set out in the table below, express 
the various ways in which drug use can result in harm19. These are clustered into five subgroups and represent physical, 
psychological and social harm, with harm to the individual separated from harm to others. The types of harm include those 
which are both directly and indirectly health related.
    Types of harm Examples    
To users* Physical Drug-specific mortality Acute alcohol poisoning, heroin overdose
    Drug-related mortality Fatal road traffic accidents, lung cancers, 
      suicides
    Damage-specific damage Cirrhosis, seizures, strokes, 
     cardiomyopathy, stomach ulcers  
    Damage-related damage Consequences of unwanted sexual activities, 
     self-harm and blood-borne viruses  
   Psychological Dependence Alcoholism, heroin addiction
    Drug-specific mental impairment Ketamine intoxication, drunkenness   
     amphetamine-induced psychosis
    Drug-related mental impairment  Mood disorders, such as depression,  
     related to drug use or lifestyle  
   Social Loss of tangibles  Loss of income, housing, employment;   
     imprisonment
    Loss of relationships  Damaged relations with friends or family 
To others Physical and  Injury  Domestic violence, road crashes, foetal harm, 
   Psychological  transmission of blood borne viruses 
   Social Crime  Acquisitive crime
    Environmental damage  Toxic waste from drug production,  
     discarded needles
    Family adversities Family breakdown, child neglect
    International damage  Deforestation, destabilisation of countries,   
     international crime
    Economic cost Costs to healthcare, police, prisons, social   
     services; indirect costs e.g. lost productivity
    Community Decline in social cohesion and community   
     reputation
Table 1: types of drug harm. Adapted from Nutt et al. 201020.
3  Background
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By scoring 20 drugs taken in the UK against the 16 harm criteria, the ACMD illustrated 
how different drugs vary in their specific combination of physical, psychological and 
social harm, and facilitated a balanced assessment of overall harm for each drug21. 
Heroin, crack cocaine and methamphetamine were identified as causing the greatest 
harm to users, whereas alcohol causes the greatest harm to others by a wide margin. 
Drug-specific mortality substantially contributes to harm from a number of drugs 
including alcohol and heroin, with economic cost also a high contributor for tobacco, 
cannabis, alcohol and heroin22. 
3.2.1 Harm to users
The majority of mortality from illegal drugs is due to accidental poisoning, which 
accounted for more than three quarters of recorded illegal drug misuse deaths in 
201223. More than four in five are related to opiate use24.
Acute and chronic physical harm varies greatly depending on the drug used, although 
many drugs cause damage to the same body regions and organs and may have similar 
harmful effects25. The severity of physical harm is also highly variable depending on the 
drug, frequency of use and dosage.
Physical harm related to drug use is not simply a direct result of drug pharmacology 
but may also result from the method of administration. Hepatitis C, for example, is a 
blood borne infection spread by the sharing of drug paraphernalia including needles 
and pipes, and which contributes greatly to drug-related mortality and morbidity. Two 
in five drug injectors in the UK are infected with hepatitis C26. While HIV transmission 
among injecting drug users remains a serious problem in many other countries, only 
1% of UK users are now infected, largely thanks to the implementation of successful 
harm reduction programmes27.
Physical harm related to drugs can also include injuries which occur when intoxication 
causes a loss of coordination or impaired judgement.
It is very difficult to 
assess the scale of the 
impact of drug use on 
longer term mental 
health.
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Substance use in the 
United Kingdom is both 
diverse and dynamic, 
with ease of availability 
and more variety than 
ever before. It is of 
paramount importance 
that we focus on 
minimising the negative 
impact on individuals 
and communities and 
we ‘future proof’ against 
emerging substance  
use issues and the 
changing profiles of 
substance users.
Jim McVeigh
Director  
Centre for Public Health 
Liverpool John Moores University
People often use drugs for positive psychological effects at the time of use, such as 
increased sociability, energy, improved mood, euphoria or hallucinations28. Conversely, 
both during and after use, some drugs can leave users feeling anxious, depressed, 
irritable, confused and/or paranoid, depending on the substance and manner of use29. 
Continued use can have further effects on mood, including chronic depression, anxiety 
and in some cases, psychosis30. Prolonged use of some drugs has also been linked 
with higher rates of suicide – individuals with a substance abuse disorder are six times 
more likely than non-drug users to attempt to take their own life31.
However, it must be noted that it is very difficult to assess the scale of the impact 
of drug use on longer term mental health, as the relationship between the two is so 
complex. While certain drugs can initiate or make existing mental health conditions 
worse – for example, there is evidence to suggest that cannabis use is a risk factor in 
developing symptoms of psychosis and that prolonged use may increase the risk of 
psychotic disorder by impacting on the persistence of symptoms32 – people with  
pre-existing mental health conditions are also more likely to turn to substance use in 
the first place33.
Prolonged use of all substances, including prescribed psychoactive and analgesic 
medications, can lead to dependence, both psychological and sometimes physical,  
with a risk of withdrawal syndrome if use is suddenly halted. The severity and 
symptoms of dependence vary greatly depending on the drug, individual, and usage 
behaviours. The scale of illegal drug dependency is difficult to define and quantify, but 
the estimated figure of 371,279 ‘high risk’ drug users in the UK (excluding Northern 
Ireland) is instructive34.
3.2.2  Harm to others
Drug use can put not just the user but others around them at serious risk of harm. 
Within intimate relationships where one partner has a problem with alcohol or other 
drugs, domestic abuse is more likely than not to occur35, and many people with 
substance misuse problems also have children36 – it is estimated that 2-3% of children 
under 16 in England and Wales have at least one parent with a serious drug problem37. 
Drug use can also harm people who are not familiar to the user – one in six road traffic 
deaths, for instance, involves at least one driver over the legal alcohol limit38.
Drug use (and enforcement) can also have significant consequences at population 
level, placing strain on health and criminal justice systems and incurring huge social 
and economic costs. Class A drug misuse (primarily heroin and crack cocaine) in 
England and Wales alone costs society an estimated £15.4 billion a year – £44,231 
per problematic user39. This figure is predominantly accounted for by the social and 
economic costs associated with drug-related crime – £13.86 billion in 2003/04, with 
fraud (£4.87 billion) and burglary (£4.07 billion) the costliest criminal acts. Drug arrests 
alone cost £535 million a year40. Of the remainder, £488 million goes on the cost of 
drug-specific and drug-related mortality and morbidity to the NHS, in providing both 
acute treatment for the primary effects of drug use, and treatment for secondary 
effects such as behavioural and mental disorders41.
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3.3 Trends in harm: illegal drugs
In the UK and throughout the Western world, levels of illegal drug use increased 
dramatically through the 1960s to the early 90s42. However, overall illegal drug use in 
England and Wales has fallen slightly over the course of the past decade, from 12.2% 
in 2003/04 to 8.6% in 2014/15 (self-reported, last year use, ages 16-59)43. A large 
proportion of this fall is due to a reduced prevalence of cannabis use, which has fallen 
from 11% in 2002/03 to 6.7% in 2014/1544. This is offset by a slight increase in Class A 
drug use, which has risen from 2.7% in 1996 to a high of 3.6% in 2008/09 and now sits 
at 3.2%45. Similar trends have been reported in Scotland and Northern Ireland46,47. It is 
therefore hard to make a case that current drugs policy has been effective in deterring 
use of those drugs deemed by the current classification system to be ‘most harmful’.
However, trends in use are not all, or the most important part of, the picture – they 
must be compared with trends in resultant harm, which are not declining in line 
with use, and are in many cases increasing. In England and Wales – which has the 
most complete and available data – the crude death rate associated with illegal 
drug misuse has more than doubled in the past 20 years, from 15.7 per one million 
population in 1993, to 39.9 per million population in 201448. 2014 saw a 17% 
increase in deaths, following a 21% increase in 201349. Within this, males are more 
than two and a half times (2.65) more likely to die through drug misuse than females, 
and those between the ages of 30 and 50 are also more at risk. Both these trends 
have been on the increase over the past twenty years50.
The increase and profile of drug-related mortality can in part be explained by 
drug-specific mortality trends. Both historically and currently, the use of cocaine 
and amphetamines, and to a lesser extent benzodiazepines, is associated with 
significantly lower mortality rates than that of heroin, which has seen a greater 
increase in deaths in the past 20 years than any other drug51. Heroin-specific mortality 
is exacerbated by patterns of high daily usage, often interrupted by prolonged periods 
of abstinence, treatment and imprisonment, all of which serve to make overdose 
increasingly likely as users return to use with the same dosage but diminished 
tolerance for the drug52.
In England, there were 7,104 hospital admissions for individuals with drug-related 
mental and behavioural disorders in 2013/14, down 11% from 2003/0453. However, 
admissions for drug poisoning have increased by 76.6% over the same period, from 
7,876 in 2003/04 to 13,917 in 2013/1454. 
In terms of harm to others, strain on the criminal justice system is a major 
consideration. There were 155,832 recorded illegal drug offences in England and 
Wales in 2015, down from 230,000 in 2013 (note that this figure includes only 
trafficking and possession offences, not other offences such as theft where drugs 
were an influencing factor)55. This is not necessarily evidence to suggest drug crime is 
reducing, but may rather be a symptom of a changing police approach. Police forces 
have increasingly been adopting alternative strategies to cannabis possession, such 
as on the spot penalties and warnings instead of prosecution, alongside the reform 
of stop and search policies. Some police forces have already gone so far as to cease 
actively pursuing cannabis users and small-scale growers56. This is recognised by the 
Office for National Statistics as a reason for the reduction in recorded crime57, and by 
association, cost.
Trends in use are not all, 
or the most important 
part of, the picture – they 
must be compared with 
trends in resultant harm, 
which are not declining 
in line with use, and are 
in many case increasing.
The crude death rate 
associated with illegal 
drug misuse has more 
than doubled in the past 
20 years.
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PERCENTAGE OF 
PEOPLE LIVING 
IN 20% MOST 
DEPRIVED AREAS  
IN ENGLAND
Drug mortality versus social deprivation
AGE-
STANDARDISED 
RATE PER  
MILLION PEOPLE
Source: ONS59,60.
Drug harm is also known to be unevenly distributed towards those from more socio-economically deprived groups. 
For instance, someone earning less than £10,000 a year is almost five times as likely to be a frequent illegal drug 
user as someone earning £50,000 or more58. It is therefore not surprising to find a correlation between deprivation 
rates and drug-related mortality rates across the regions of England, as shown here.
 AREA DEPRIVATION DEATHS  
 North East 31.0 69.3 
 North West 31.9 60.9
 Yorkshire 28.1 38.1
and Humber
 East 18.3 29.4
 Midlands
 West 29.3 44.7 Midlands
 South West 10.6 34.9
 South East 7.7 38.3
 London 22.9 25.4
 East of 10.2 37.7
 England
Page 14 TAKING A NEW LINE ON DRUGS: 3 BACKGROUND  RSPH 2016
3.4  In perspective: harm from legal drugs
The use of alcohol and tobacco – legal drugs – is deeply embedded in our society. 
Despite increased awareness of significant harm to users, they continue to be used 
widely by all sections of the population. High levels of harm, both to users and those 
around them, are prevalent due to the ease of acquisition and social acceptability that 
accompanies their legal status. At individual and population level, alcohol and tobacco 
cause greater health and social harm than many of their illegal counterparts61.  
It can be suggested that tobacco has far more dependent users than any other drug 
in the UK; of the 10 million smokers in the UK, around 6 million may be classed as 
dependent on the basis that 60% say they would find it hard to go a day without 
smoking, 63% say they want to quit, and 69% have their first cigarette of the day 
within an hour of waking62. This compares to the 6% of UK adults who show signs of 
alcohol dependence, equating to about 3.1 million people63,64.
Despite significant declines in use, smoking remains the leading cause of preventable 
illness and early death in the UK, killing more people each year than the next five 
causes of preventable death combined65. A 50-year study of lifetime smokers has 
shown that between half and two thirds will be killed by their habit – a higher 
proportion than from almost any other drug66. 
Alcohol is the third largest risk factor for preventable disease, responsible for 10% 
of the UK burden of disease and death, and for a quarter of all deaths among men 
aged 16-24. The proportion of people dying from a range of alcohol-related causes 
remains significantly greater than it was 20 years ago in all four UK nations, with a 
19% increase in alcohol-related deaths in England from 2001 to 201267. Scotland is the 
only nation to have seen significant falls over the past decade, but still has the highest 
mortality rates68.
While the impact of passive smoking has been lessened by restrictions on indoor 
smoking and smoking in cars with children present, alcohol remains a significant risk 
factor for injury to others – for instance, more than half of all violent crime in 2015 was 
alcohol-related69. Harm to children remains significant, with over half of child protection 
cases involving alcohol or misuse of another substance70. Diagnosed cases of foetal 
alcohol syndrome have also tripled in England over the past 16 years71.
High and frequent societal use of alcohol and tobacco puts intense strain on public 
services in the UK. Alcohol misuse costs England alone around £21 billion per year in 
healthcare, crime and lost productivity72. The cost of smoking to society in England is 
estimated to be £13.9 billion a year, which includes the £2 billion a year spent by the 
NHS on treating smoking-related disease73. The joint figure of almost £34 billion a year 
for these two legal drugs is more than twice the £15.4 billion associated with all Class 
A drug use combined.
At individual and 
population level, alcohol 
and tobacco cause 
greater health and social 
harm than many of their 
illegal counterparts.
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ONLY 1IN 4  
members of the 
public believe 
current UK drugs 
and alcohol 
policy is effective 
at preventing 
harm to health 
and wellbeing
Source: RSPH public opinion survey76.
4  The current approach
This section examines how the UK has attempted to deal with illegal drugs to date, 
contrasts this with developments in other countries, and suggests why the UK needs 
to think again about drugs strategy.
4.1 Current UK strategy
Despite the profound health consequences related to drug misuse, responsibility for 
developing drugs strategy for the UK lies primarily with the Home Office, rather than 
the Department of Health. The UK Government has responsibility for setting the overall 
strategic direction of drug policy, although the manner of its delivery outside of England 
is largely a responsibility of the devolved national governments, with Scotland, Wales 
and Northern Ireland also having their own drugs and alcohol strategies.
The current UK drugs strategy states its overall objectives as follows:
•	 Reducing demand, particularly among vulnerable young people, families and  
 those involved in the criminal justice system.
•	 Restricting supply by tackling the criminal organisations importing and  
 supplying drugs.
•	 Building recovery in communities through the new ‘locally-led’ system and  
 a greater focus on the wider determinants of drug-use74.
In terms of delivering on these objectives, the UK public is currently unconvinced – only 
a quarter believe current UK drugs and alcohol policy is effective at preventing harm to 
the public’s health and wellbeing75.
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4.2  The legal framework
At the time of writing, the legal framework for drugs policy in the UK is in a state 
of some confusion. Spurred by increasing concern about NPS, the Psychoactive 
Substances Act (PSA) finally came into effect on 26 May 2016, having been delayed 
while attempts were made to address concerns over enforceability.
Under the PSA, it is now a crime to produce, supply or import any drug that ‘acts on the 
central nervous system to change mental functioning or emotional state’, a definition 
meant to encompass all current and future NPS, and which abandons any attempt at 
evidence-based assessment of relative harm – any psychoactive effect is assumed 
to be inherently harmful. The Act provides exceptions for food, medicinal products, 
healthcare activities and research, as well as for alcohol and tobacco77. It does not 
change the status of drugs that are already illegal.
However, it is not a criminal offence to possess substances covered by the PSA. This 
may create a confusing situation for law enforcement when an individual is found in 
possession of a given substance – possession is a criminal offence only if it is an illegal 
drug under the Misuse of Drugs Act and not a psychoactive substance covered by the 
PSA, but the two may be virtually indistinguishable at the time.
The pre-existing legal framework for illegal drugs is based on the Misuse of Drugs Act 
1971, introduced to prevent the non-medical use of potentially harmful drugs. The Act 
divides illegal drugs into three classes, A, B and C, as determined ‘according to their 
accepted dangers and harmfulness in the light of current knowledge’, with Class A 
regarded as the most harmful78. The ACMD advises the government on this, although 
classifications do not always wholly reflect this advice. These classes have been used 
by subsequent governments to set enforcement priorities and penalties, and inform 
public health messaging79. 
The Misuse of Drugs Act is complemented by the Misuse of Drugs Regulations 
2001, which authorises certain individuals to supply and possess certain controlled 
substances – for instance, doctors who can prescribe them for medical reasons. This 
is done under a system of five ‘schedules’ ranging from drugs that have no accepted 
use (schedule 1), through prescription-only drugs, to low-strength preparations that 
require only minimal controls (schedule 5). Unauthorised production, supply, import or 
possession of these controlled substances is an offence80.
Illegal drugs therefore belong to both a legal class and a medicinal schedule. While the 
function of scheduling to protect the public, while also permitting access to drugs with 
legitimate therapeutic value, is clear (albeit inconsistent in application), the purpose of 
the classification system is becoming increasingly less so. Reports from both the  
House of Commons Science and Technology Committee and the RSA Commission 
have found this system ‘not fit for purpose’81. Analysis has suggested there is almost 
no correlation between overall associated harm and the class of drugs (including legal 
drugs) in the UK82.
There is almost no 
correlation between 
overall associated harm 
and the class of drugs 
in the UK.
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4.2.1  Enforcement and deterrence
In reality, enforcement practice has been evolving independently from drug 
classification. This is most notable in the case of cannabis, for which the National 
Police Chief’s Council (NPCC) (formerly the Association of Chief Police Officers) 
has issued specific guidance acknowledging that priorities are divorced from the 
classification system83.
It is not evident that a drug’s legal classification has any effect on its level of 
availability or use, and the impact of classification changes is not monitored by the 
Government. The rationale of the current classification system is that more harmful 
drugs should carry greater penalties, thereby more strongly deterring use and supply. 
However, in practice:
•	 Maximum	penalties	for	both	use	and	supply	are	very	poorly	correlated	with	the		 	
 level of harm associated with illegal drugs84.
•	 Harsher	penalties	for	illegal	drug	use	do	not	appear	to	deter	use,	a	point 
 supported by evidence from international comparisons85. Only one in 10 UK 
 adults say that a drug’s legal classification has any influence on how   
 likely they are to use it86.
•	 Penalising	use	is	too	blunt	a	tool	to	address	the	nuanced	harm	associated	with		 	
 substance misuse, and causes further harm to those who are criminalised, a point  
 explored further in section 5.3 of this report.
It is not evident that a 
drug’s legal classification 
has any effect on its level 
of availability or use.
With enforcement resources scarce, Durham Constabulary have ceased actively pursuing and 
prosecuting cannabis users and small-scale growers. Drug enforcement priorities are instead 
being focused on street gangs, dealers and the large profits resulting from the illegal drug trade.   
“I believe that vulnerable people should be supported to change their 
lifestyles and break their habits rather than face criminal prosecution,  
at great expense to themselves and to society. 
“The scant resources of the police and the courts are better used 
tackling the causes of the greatest harm – like the organised crime 
gangs that keep drugs on our streets and cause misery to thousands  
of people – rather than giving priority to arresting low-level users.”
Ron Hogg 
Police and Crime Commissioner
Durham Constabulary
4.2.2  Public confusion
Given the poor correlation between drug harm and classification, the current system 
risks sending misleading signals to the public about relative harm, and this may 
be contributing to avoidable risk. This is particularly the case for the two in five 
people who state that a drug’s classification influences how harmful they think it is 
compared to other substances87. This disconnect may be behind a number of popular 
misperceptions, such as most people rating mephedrone as less harmful than LSD, 
despite research suggesting it has the potential to pose greater risks88.
Classification, when done badly, can undermine both trust in the information provided 
and the public’s ability to make informed choices. Public consultation has found that 
the majority find the current system ‘confused, inconsistent and arbitrary’89.
The classification system also gives rise to a misleading linear perception of harm by 
failing to separate out different types of harm. GHB, for example, is a Class C drug, 
which ranks somewhere between cocaine (Class A) and ketamine (Class B) in terms of 
overall harm to users. Its lethal overdose potential is extremely high compared to many 
other drugs90, including higher classification drugs such as cannabis (Class B), and yet 
this vital subtlety is not conveyed by its Class C classification. 
Furthermore, the current classification system gives the public no way of comparing 
the severity of harm from illegal drugs with that from legal drugs. This may contribute 
to the popular belief that alcohol and tobacco are less harmful, despite overwhelming 
evidence to the contrary91,92. In the context of NPS, it has also made it difficult to 
adequately convey risk and dispel the misconception that they are safer than traditional 
illegal drugs.
Under the PSA, the supply of all NPS is now illegal by default, with penalties decided 
outside of the existing classification system. This leaves a confusing legal environment 
that treats NPS, Class A, B, C, and legal drugs in a variety of ways that do not accurately 
reflect harm or easily evolve in line with emerging evidence.
Classification, when 
done badly, can 
undermine both trust 
in the information 
provided and the 
public’s ability to make 
informed choices.
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4.3 International context
The modern-day prohibitionist approach to drugs policy has its legal foundation in 
the 1961, 1971 and 1988 United Nations drug treaties, ratified and incorporated into 
the domestic laws of more than 150 countries. This international legal framework 
mandates criminal sanctions for the production and supply of a range of psychoactive 
substances, and at least some form of sanction (which may not be criminal) for their 
possession or use. This has led to high incarceration rates worldwide93. In the US, 
for instance, it is not uncommon for individuals to be given a custodial sentence, 
sometimes for life, for cannabis related offences94.
However, in recent years there has been a notable shift from policy makers and 
political leaders across the globe in their approach to drugs, drug users and 
associated harm and penalties. In 2012, the United Nations Office on Drugs and Crime 
(UNODC) acknowledged the “growing recognition that treatment and rehabilitation of 
illicit drug users are more effective than punishment”95. The World Health Organisation 
now advocates a ‘rebalancing’ of global and national drugs policies towards public 
health and harm reduction, criticising an over-focus on punitive enforcement for 
hampering the effectiveness of evidence-based harm reduction interventions, 
stating that this bias has led to “…policies and enforcement practices that entrench 
discrimination, propagate human rights violations, contribute to violence related to 
criminal networks and deny people access to the interventions they need to improve 
their health”96.  
4.3.1  Moves towards harm reduction
Harm reduction is an approach to drugs policy that focuses primarily on reducing the 
overall level of harm associated with drug use, rather than the level of drug use itself, 
accepting that a certain level of use will always remain inevitable among those who are 
unable or unwilling to stop97.
In recent years, more than 90 countries – including the Netherlands, Canada, 
Switzerland, Uruguay, Spain, Australia and some US States – have adopted an 
approach to drugs policy that specifically includes a focus on harm reduction98. 
Countries that have long subscribed to heavily enforced supply-side policies and 
punishment for those caught using drugs are beginning to reconcile elements of 
harm reduction within their frameworks, or pioneering totally new frameworks, with 
encouraging results. The following table sets out a number of these.
... policies and 
enforcement practices 
that entrench 
discrimination, propagate 
human rights violations, 
contribute to violence 
related to criminal 
networks and deny 
people access to the 
interventions they need 
to improve their health.
World Health Organization, 2016
APPROACH 
•	 Expands	harm	reduction	approach	 
 for people who inject heroin
•	 Introduces	pioneering	heroin-assisted 
 therapy (HAT) programmes and safe  
 consumption facilities
•	 Prioritises	public	health	and	cost-	
 saving above punitive enforcement
RESULT 
•	 Health	outcomes	for	heroin	addicts		
 on HAT programmes greatly improve 
•	 Criminal	activity	of	HAT	participants		
 drops, more than covering cost  
 of treatment 
•	 HAT	provision	reduces	importation	 
 of illicit heroin, and new cases of  
 heroin use fall
APPROACH 
•	 Federal	government	adopts	harm		
 reduction approach, including   
 legalisation and regulation of   
 cannabis
•	 Improves	interdepartmental		 	
 cooperation and coordination   
 to address public health and  
 public order
•	 Focuses	on	prevention,	treatment,		
 harm reduction and enforcement  
 priorities
RESULT 
•	 Supervised	injecting	facilities	 
 deemed ‘life-preserving’ by  
 Supreme Court of Canada 
•	 City	that	pioneered	supervised		
 injecting (Vancouver) sees HIV and  
 chronic Hepatitis C rates plummet 
APPROACH 
•	 Effectively	decriminalises	cannabis,		
 tolerates sale from licensed  
 ‘coffee shops’ 
•	 Aims	to	dissuade	use	of	riskier	drugs
•	 Aims	to	reduce	harm	to	users
•	 Aims	to	diminish	nuisance	by	 
 drug users
•	 Aims	to	combat	production	and		
 trafficking of drugs by separating  
 cannabis and hard drugs markets
RESULT 
•	 Levels	of	problem	drug	use	below		
 those of the UK (both general and  
 cannabis specific) 
•	 Treatment	programmes	associated		
 with reduction in crime 
•	 Separation	of	cannabis	trade	from		
 hard drugs trade leads to low   
 prevalence of hard drug use   
•	 ‘Coffee	shops’	generate	around		
 £300m in tax annually - used to fund  
 public health and social inclusion 
NETHERLANDS
CANADA
SWITZERLAND
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When Portugal adopted a  
health-led approach to 
drugs in 2001 it did so 
because it wanted a 
humane, mature, evidence 
based strategy to reduce 
drug harms. In the UK, the 
government’s most recent 
legislation, the Psychoactive 
Substances Act, appears to 
be unworkable and couldn’t 
be more in contrast to these 
ambitions.
Helen Mills 
Research Associate 
Centre for Crime  
and Justice Studies
4.3.2  Portugal and the case for decriminalisation
In 2001, Portugal took the decision to remove criminal sanctions for the personal 
possession and use of all illegal drugs and instead focus on harm-reduction and 
health promotion. It had become clear that the country’s previous approach of strong 
prohibition, enforcement and prosecution had failed: by 1999, Portugal had reached 
crisis point, with almost 100,000 heroin addicts and the highest rate of drug-related 
AIDS deaths in Europe109. In the years since decriminalisation and reorientation of 
resources to health promotion and harm reduction:
•	 New	cases	of	HIV	among	those	who	inject	drugs	have	declined	dramatically,	 
 from 1,016 in 2001 to 56 in 2012.
•	 Problem	drug	use	has	declined	in	15-24	year	olds.
•	 Deaths	due	to	drug	use	have	fallen	significantly,	from	80	in	2001	to	16	in	2012.
•	 Cases	of	hepatitis	C	and	B	have	both	fallen	in	the	drug	using	population.
•	 Overall	levels	of	drug	use	are	now	below	the	European	average110.
•	 Social	costs,	including	both	indirect	health	costs	and	direct	costs	associated	 
 with the legal system, have fallen by 18%111.
Newly dignosed cases of HIV and AIDS among people who use drugs
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Source: adapted from Transform 2014112. 
4.4 The need for a new approach
From a public health perspective, the purpose of a good drugs strategy should be to 
improve and protect the public’s health and wellbeing by preventing and reducing the 
harm linked to substance use, whilst also facilitating any potential medicinal benefits. 
The current approach is failing to do this in a number of ways:
•	 Health	harm	related	to	drug	use	is	rising;
•	 Harm	remains	concentrated	among	specific	and	often	vulnerable	groups;
•	 Additional	and	unnecessary	harm	is	being	caused	to	people	who	use	drugs	by		 	
 stigmatization, criminalisation, and illicit drug markets;
•	 Opportunities	to	reduce	harm	are	being	missed	because	the	public	are	confused		 	
 about the relative risk of harm from different drugs, including legal ones;
•	 Finite	resources	are	not	being	effectively	targeted	at	reducing	harm.
To address these failings, resources should be re-focused on creating an environment 
that minimises drug-related harm as far as possible, and on building a comprehensive 
system that supports people to avoid, reduce and recover from drug-related harm. 
This approach should include reducing use, where this is the most practical and 
effective route, while also recognising reasons for use. Specific aspects of the 
approach RSPH would like to see are set out in section 5.
Resources should be 
re-focused on creating 
an environment that 
minimizes drug-related 
harm as far as possible, 
and on building a 
comprehensive system 
that supports people 
to avoid, reduce and 
recover from drug-
related harm.
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This section sets out an alternative potential approach to drugs policy which places 
emphasis on supporting the public’s health, reducing harm from drugs and moving 
away from criminalising users.
5.1 Closely aligned, health-led strategies
As we have seen in section 3 of this report, the personal and societal harm 
associated with legal drugs such as alcohol and tobacco is just as great, if not 
greater, than the harm associated with many illegal drugs. The misuse of legal and 
illegal drugs often occurs together, which can multiply their respective harm113– 
illegal drugs were combined with alcohol in more than a third (36%) of drug misuse 
deaths in 2012, a proportion that has remained similar in recent years114.
However, the current UK approach consists of separate strategies for alcohol, 
tobacco and illegal drugs, with the drugs strategy led by the Home Office rather 
than the Department of Health. Resources are focused on enforcement relating 
to drugs that are currently illegal but which are in many ways less harmful than 
alcohol or tobacco. Every year, the UK spends upwards of £4 billion on enforcement, 
courts, probation and prison related to illegal drugs115. Some of this resource could 
potentially be re-focused on illegal activities related to legal drugs. For example, 
10-15% of licensed premises in the UK persistently sell alcohol to underage buyers, 
yet only 0.5% are called up for review116.The strong enforcement of the minimum 
purchase age for alcohol has been found to be very effective at limiting harm, and 
given its broad reach, the public health impact can be very high117.
This over-focus on illegal drugs is out of step with the balance of public opinion: 
80% of the general public agree that the more harmful a drug is to health, the more 
tightly controlled it should be. In theory, this could place alcohol and tobacco under 
tighter controls than a number of currently illegal drugs. This is clearly unrealistic 
as these are deeply socially-embedded substances, and the criminal markets that 
could emerge would likely cause more harm than good. While alcohol, tobacco 
and illegal drugs still require tailored approaches and dedicated resources, it is 
important to recognise legal and illegal drugs as two sides of the same coin, which 
cause comparable and often interlinked harm.
This should be reflected at a strategic level, with illegal drugs strategy sitting 
alongside alcohol and tobacco strategies under the lead of the Department of 
Health – with ring-fenced funding transferred accordingly. These strategies should 
not be siloed but closely interlinked and guided by a set of common principles. This 
would create greater opportunities to share learning and best practice and develop 
interventions that address cross-cutting issues of addiction and substance misuse.
Transfer lead 
responsibility for UK 
illegal drugs strategy 
to the Department 
of Health, and more 
closely align with 
alcohol and tobacco 
strategies
Illegal drugs were 
combined with alcohol in 
more than a third of drug 
misuse deaths in 2012.
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Bringing strategies for alcohol, tobacco and other drugs closer together in this way 
would help fundamentally reframe the way we perceive and address substance misuse 
in terms of relative harm, and allow resources to be targeted where they can have 
the greatest impact. It would help de-stigmatise illegal drug users and de-normalise 
alcohol abusers, with positive implications for take-up of treatment for each.
Wales has already adopted this approach, going so far as to adopt a unified substance 
misuse strategy encompassing both alcohol and illegal drugs. When developing the  
10 year (2008-18) strategy, ‘Working Together to Reduce Harm’, policy makers made 
no distinction between harm caused by illegal drugs and that caused by alcohol, which 
accounted for 467 deaths in 2013118. Since the implementation of the strategy, Wales 
has seen deaths from drug misuse decrease by 30%119, and alcohol consumption has 
fallen on all three measures: drinking above guidelines, heavy (binge) drinking, and 
very heavy drinking120.
5  A public health approach to drugs strategy
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It would help  
de-stigmatise illegal drug 
users and de-normalise 
alcohol abusers, with 
positive implications for 
take-up of treatment  
for each.
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5.2 Prevention through universal education
A vitally important aspect of any drugs strategy is giving young people, who are among 
those most at risk, the tools and understanding they need to make informed choices 
about drug use (legal and illegal) and avoid or minimise harm. As has already been 
seen earlier in this report, the current legal classification system is woefully inadequate 
for this purpose, and must be reformed and supported by a comprehensive education 
strategy, of which the user-level drug harm profiles outlined in section 5.3 could  
form a part.
However, current drugs education provision in the UK is inconsistent121. Drugs and 
addiction do not feature in the mandatory curriculum. Instead, drugs education is at the 
discretion of individual head teachers who can decide whether or not it is covered in 
Personal, Social, Health and Economic (PSHE) education.
Of those educational activities that are provided, the vast majority have not been 
evaluated, and a number that have been evaluated have been shown to be ineffective, 
or even counterproductive122. To be effective in preventing substance misuse, drugs 
education must be interactive and take an approach that focuses more broadly on 
developing resilience, self-efficacy, impulse control and life skills in relation to risk 
taking behaviour123.
There is a clear and pressing need then, for the provision of drugs education that is 
both universally available to all young people, and in line with prevention best practice. 
The Alcohol and Drug Education and Prevention Information Service (ADEPIS), run by 
the charity Mentor and funded by the Department for Education, has been established 
to issue guidance on effective drugs education in schools, and advises that proper 
PSHE education is crucial in helping young people develop the necessary values and 
skills to avoid drug harm124.
RSPH strongly advocates that PSHE education be made a statutory requirement in 
schools at all key stages. Statutory PSHE education, supported by access to evidence-
based resilience programmes, is an important component in addressing not just drug 
harm but the whole spectrum of young people’s health and wellbeing issues, from 
sexual and mental health to childhood obesity.
Population-wide education through universal PSHE education must also be 
complemented by specific interventions targeted at those young people who are at 
particularly high risk of drug misuse, for instance those who have at least one parent 
with a substance misuse issue.
There is a clear and 
pressing need for the 
provision of drugs 
education that is both 
universally available to 
all young people, and in 
line with prevention best 
practice.
Introduce statutory, 
comprehensive, 
Personal, Social, 
Health and Economic 
(PSHE) education 
in schools, with 
evidence-based 
drugs education 
as a mandatory 
component
Inform strategies and 
enforcement priorities 
using holistic, 
evidence-based drug 
harm profiles and 
rankings and use 
these for public health 
messaging, rather 
than the current ‘A, B, 
C’ legal classification
5.3 Beyond legal classification:  
  evidence-based drug harm profiles
The closer alignment of substance misuse strategies would require priorities to  
be informed not by the existing legal classification system, but by a coherent set  
of evidence-based rankings and comparative harm profiles for both legal and  
illegal drugs.
The Independent Scientific Committee on Drugs has provided a basis on which this 
could be done. Using a process of multi-criteria decision analysis, they arrived at 
weighted scores, for a range of legal and illegal drugs, for each of the 16 types of harm 
agreed upon by the ACMD and set out in section 3 of this report. These scores were 
then added to provide an overall harm score and ranking for each drug126. The top 10 
most harmful drugs according to this method, and the types of harm that contribute 
most to their overall score, are illustrated on the next page.
1IN10 
people say  
a drug’s class 
influences 
how likely 
they are 
to use it 
compared to 
other illegal 
drugs.
The introduction of evidence-
based drug harm profiles 
would enable people to better 
understand the risks of harm 
associated with different 
substances, particularly new 
psychoactive substances which 
many people think are safe due 
to them regularly being referred 
to as ‘legal highs’. Talking 
about all drugs in a holistic, 
health-focused way may also 
help reduce the stigma around 
drug use and encourage more 
people to seek support for 
substance misuse.
Hattie Moyes 
Research and  
Development Manager  
Rehabilitation for Addicted  
Prisoners Trust
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2 IN 5  
say a 
drug’s class 
influences 
how harmful 
they think  
it is 
compared 
to other 
substances.
3 IN 5  
agree the 
drugs 
classification 
system should 
be replaced 
by some-thing 
that better 
reflects health 
risks.
Page 27TAKING A NEW LINE ON DRUGS: 5 A PUBLIC HEALTH APPROACH TO DRUGS STRATEGY  RSPH 2016
ECONOMIC COST
INJURY TO OTHERS
FAMILY PROBLEMS
CRIME
INDIRECT FATALITIES
DIRECT FATALITIES
DEPENDENCE
FINANCIAL DIFFICULTIES
INDIRECT MENTAL HEALTH HARM
DIRECT MENTAL HEALTH HARM
DEPENDENCE
FINANCIAL DIFFICULTIES
INDIRECT MENTAL HEALTH HARM
DIRECT MENTAL HEALTH HARM
DEPENDENCE
LOSS OF RELATIONSHIPS
INTERNATIONAL DAMAGE
DEPENDENCE
LOSS OF RELATIONSHIPS
INDIRECT PHYSICAL HEALTH HARM
DIRECT MENTAL HEALTH HARM
INDIRECT FATALITIES
DEPENDENCE
DIRECT PHYSICAL HEALTH HARM
DIRECT MENTAL HEALTH HARM
LOSS OF RELATIONSHIPS
INDIRECT PHYSICAL HEALTH HARM
DEPENDENCE
DIRECT FATALITIES
ECONOMIC COST
INDIRECT MENTAL HEALTH HARM
DIRECT MENTAL HEALTH HARM
DEPENDENCE
CRIME
DIRECT MENTAL IMPAIRMENT
INDIRECT FATALITIES
DIRECT FATALITIES
DIRECT MENTAL HEALTH HARM
INDIRECT MENTAL HEALTH HARM
DEPENDENCE
TYPES OF HARM  0=NO HARM  13=VERY SERIOUS HARM OVERALL 
HARM
13
12
9
5
6
5
6
4
6
6
6
4
6
4
4
4
4
3
3
3
2
6
6
4
3
3
2
2
2
3
2
2
2
2
4
3
3
3
3
3
The top 10 most harmful drugs and the harms that account 
for at least 50% of their overall harm:
Based on the model reported in Nutt, D. J., King, L. A., Phillips, L. D., & on behalf of the Independent Scientific 
Committee on Drugs. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(1558-65). 
Grey text=harm to user 
Black text=harm to others
ECONOMIC COST 5
CRIME 8
CRIME 10
ALCOHOL 72
 HEROIN 55
CRACK COCAINE 54
METHYLAMPHETAMINE 33
COCAINE 27
TOBACCO 26
AMPHETAMINE 23
CANNABIS 20
GHB 18
BENZODIAZEPINES 15
As well as being used to inform drug strategy and enforcement, these rankings could be used to provide the public with 
easily accessible information on the specific, relative risks of harm associated with different drugs, including legal ones. 
They could be used to produce user-level drug harm profiles, disseminated through public health messaging and education 
in schools and other community settings, and targeted particularly at high-risk groups. This would help promote a holistic 
understanding of drug harm, rather than a simplistic and misleading sense that every type of harm correlates with legal 
classification. The drug harm profiles provided here are an example of how this could be done, and would require a robust 
process of piloting and refinement before any wider implementation.
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Drug harm profile key:
•= Social harms to users•= Social harms to others•= Physical harms to users•= Psychological harms to users•= Physical and psychological harms to others
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5.4 Decriminalising drug users
Criminal penalties for drug possession, ranging from a discharge to imprisonment for 
several years, are currently employed in an attempt to create an environment that 
strongly deters illegal drug use, and thereby protects individuals and others around 
them from associated harm. However, there is an emerging body of evidence that 
criminal sanctions are not effective in these aims, including a review of international 
drug policies commissioned by the Home Office that concluded there is no evidence 
tougher sanctions deter use128.
There is no evidence that the small reductions in overall illegal drug use in the UK since 
the late 1990s have been related to criminal penalties for personal possession, which 
have stayed broadly similar, if not weakened. In cases where penalties have been 
reduced, for instance when cannabis cautions became available as an alternative to 
criminal sanctions, the use of cannabis continued to decline129. 
There is good reason to suggest that moving away from criminalising drug users could 
reduce key forms of health-related harm, by removing those forms of harm that are 
caused or exacerbated by criminalisation itself:
•	 Criminalising	drug	users	can	undermine	chances	for	good	health	 
 and wellbeing, both in the short and long term. Even for people who receive  
 non-custodial sentences, including formal cautions, gaining or adding to a criminal 
 record can cause serious damage to life chances. They may lose their current job, 
 and face numerous barriers to moving on including access to colleges and   
 universities, training, employment, housing, personal finance and travel130.
•	 For	the	more	than	1,000	people	imprisoned	for	personal	drug	use	in	England		 	
 and Wales each year131, the impact can be far more serious, especially for the   
 young, among whom rates of illicit drug use are highest. The recent Harris Review   
 concluded that imprisonment for 18-25 year olds interrupts development, severs  
 ties with the family and community, and brings trauma and exposure to gang   
 violence in prisons132. Although recovery and rehabilitation programmes exist within  
 prisons, access to drugs is widespread, with a particular acute emerging challenge 
 relating to NPS133. The stressful and disorientating period after release can be 
 traumatic, and, for people with a history of opiate misuse, fatal – the risk of   
 overdose is hugely increased among prisoners on recent release134.
•	 Criminalisation exacerbates health and wellbeing inequalities, since its effects 
 are more likely to be felt among certain ethnic and socio-economically    
 disadvantaged groups. Illegal drug use is lower among black and minority ethnic   
 (BAME) groups than the white population135, and yet black people are six times more  
 likely to be stopped and searched for drugs. In London, black people are charged   
 five times more often for possession of cannabis than white people136.
•	 The criminal status of drug use may deter people from coming forward for 
 treatment. An RSPH survey found one in five young people would be put off seeking  
 help due to the stigma of having illegal drugs on their record, and almost one in four  
 by the legal status of the drug. Only one in 20 felt confident they would receive the   
 help they would need for illegal drug use, without judgement or stigma137.
Source: RSPH public opinion survey127.
Decriminalise the 
personal possession 
and use of illegal 
substances and where 
helpful, divert users 
into the health system. 
The evidence relating 
to any potential health 
benefits or harm from 
legal, regulated supply 
should be kept under 
review
Almost  
1 IN 4  
young 
people 
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be put 
off 
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drug  
use  
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illegal 
status.
Only  
1IN 20 
young 
people are 
confident 
they would 
receive the 
help they 
would 
need for 
illegal 
drug use, 
without 
judgement 
or stigma.
Given that criminalisation has not proved as effective as could be desired in reducing 
use of the most harmful illegal drugs, and is responsible for a large degree of additional 
long-term harm to health and wellbeing, distributed unequally across socio-economic 
groups, a sea change in approach is required. Personal possession and use of illegal 
drugs should therefore be decriminalised, and the UK should move towards a harm-
reduction approach similar to that of Portugal, where drug possession for personal use 
is now a civil matter, not a criminal one.
Under such a system, users are referred to dissuasion panels – focussed on tailored 
treatment and support to quit, not punishment – and can be sanctioned for non-
attendance. 60% of the public support trialling this approach in UK cities138. Some police 
forces have also expressed support for such an approach139,140, as it would free up 
finite police resources to focus on more serious drug offences – dealers, suppliers and 
importers would continue to be pursued and prosecuted.
International evidence from countries such as Portugal and the Czech Republic suggests 
that decriminalisation does not lead to a significant increase in illegal drug use141. 
A body of international evidence is also beginning to emerge as to the potential benefits 
and harms of taking supply of certain drugs out of the hands of organised crime by 
establishing legal, regulated markets142. The Government should keep this evidence 
under review.
Drugs policy should completely 
be considered a health issue. The 
involvement of law enforcement
and any kind of punitive reaction to drugs in 
our society damages the health of individuals 
and the fabric of communities.
Neil Woods Chairman and Former  
Undercover Drugs Detective Sergeant 
Law Enforcement Against Prohibition UK
We welcome the Society’s 
call for the end of criminal 
sanctions for drug possession 
offences; criminalisation 
has no deterrent effect 
and the evidence from 
other countries shows that 
decriminalisation can have 
better health and social 
outcomes.
Niamh Eastwood 
Executive Director 
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5.5 Supporting individuals to reduce  
  and recover from drug harm
A humane, health-led approach to drugs strategy must ensure that individuals who 
do suffer drug-related harm are efficiently signposted to appropriate support and 
treatment to reduce and recover from that harm, rather than being criminalised.
However, there remain significant barriers to treatment for many users, despite 
significant progress in recent years in getting some of the most high risk individuals 
into services143. There are still large numbers of people experiencing problems with 
substance misuse who are not getting the help they need for a number of reasons 
including social stigma144, mental health problems, and attitudes to treatment145.
With local authorities facing ongoing cuts to their public health budgets, from which 
drug treatment services are funded, this situation may get worse. However, there are 
significant opportunities for members of the 15 million-strong wider public health 
workforce to help mitigate this gap in service provision, if they are provided with the 
right training and support. Professionals such as health trainers, who are trained from 
within communities to support people to improve health behaviours, can be key assets 
for individuals who may lack the knowledge, motivation or confidence to effectively 
navigate services. 
Those who work with vulnerable young people, in particular, including foster carers  
and staff in residential homes, need training to be better able to deal with substance 
misuse issues.
Source: RSPH public opinion survey146.
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Only 
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6  The new lines: summary of recommendations
This section summarises the five key pillars of RSPH’s public health approach to 
drugs strategy. These recommendations are fully explored in section 5.
Closely aligned, health-led strategies
1. Transfer lead responsibility for UK illegal drugs strategy 
 to the Department of Health, and more closely align   
 with alcohol and tobacco strategies.
Prevention through universal education
2. Introduce comprehensive, statutory PSHE in schools,   
 with evidence-based drugs education as a mandatory   
 component.
Beyond legal classification: evidence-based  
drug harm profiles
3. Inform strategies and enforcement priorities using 
 holistic, evidence-based drug harm profiles and    
 rankings and use these for public health messaging,   
 rather than the current ‘A, B, C’ legal classification.
Decriminalising drug users
4. Decriminalise the personal possession and use of  
 illegal substances and where helpful, divert users into 
 the health system. The evidence relating to any    
 potential health benefits or harm from legal, regulated   
 supply should be kept under review.
Supporting individuals to reduce and  
recover from harm
5. Exploit the potential of the wider public health workforce  
 to support and direct drug users into treatment services.
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The report of the Royal Society for Public Health is very much 
welcomed. It argues that the valuable work of health professionals in 
dealing with the health and social consequences of the harm caused 
by drugs is impeded rather than assisted by a muddled prohibitionist 
framework that criminalises some users of psychoactive drugs 
whilst very harmful psychoactive drugs including alcohol and 
tobacco remain legal. It calls for a rational, evidence-based approach 
to address the harm from all psychoactive substances, led by the 
Department of Health, focussing resources on a health approach to 
drug harm based on the decriminalisation of the personal possession 
of drugs. The resources released should be used to enhance the 
role of the wider public health workforce to assist in the harm 
reduction and recovery of problematic drug users and the support to 
communities damaged by the illicit drug trade.
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